Importantly, AβO-selective antibodies can prevent AD-like pathology in mice and ameliorates cognitive deficits in AD mice for at least 40 days (Xiao et al., 2013; Zhao et al., 2014; Sebollela et al., 2017; Cline et al., 2018; Viola et al., 2021). The gene discussed is ABO; the disease is Cognitive impairment.